Pharmacologic treatment of depression during pregnancy

JAMA

Volumn 282, Issue 13, 1999, Pages 1264-1269

  Wisner, Katherine L ^a,e   Gelenberg, Alan J ^b   Leonard, Henrietta ^c   Zarin, Deborah ^d   Frank, Ellen ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c BROWN UNIVERSITY   (United States)

^d AMERICAN PSYCHIATRIC ASSOCIATION   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

BIRTH DEFECT; DEPRESSION; FEMALE; FETUS DEATH; FETUS RISK; HUMAN; LOW BIRTH WEIGHT; MATERNAL WELFARE; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TERATOGENICITY; WITHDRAWAL SYNDROME;

EID: 0033530293     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.282.13.1264     Document Type: Review

References (48)

1. Burke KC, Burke JD, Rae DS, Regier DA. Comparing age at onset of major depression and other psychiatric disorders by birth cohorts in five US community populations. Arch Gen Psychiatry. 1991 ;48:789-795.
2. O'Hara MW, Neunaber DJ, Zekoski EM. Prospective study of postpartum depression: prevalence, course, and predictive factors. 7 Abnorm PsycftoJ. 1984;93:158-171.
3. Wisner KL, Peindl KP, Hanusa BH. Relationship of psychiatric illness to childbearing status: a hospital-based epidemiologic study. 1 Affect Disord. 1993;28:39-50.
4. The baby or the drug? It's a choice that many pregnant women often face-but shouldn't. US News & World Report. March 27,1995.
5. Frank E, Kupfer DJ, Perel JM, et al. Three year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 1990;47:1093-1099.
6. American Psychiatric Association. Practice guidelines for major depressive disorder in adults. Am J Psychiatry. 1993;150(suppl):4.
7. Pastuszak A, Schick-Boschetto B, Zuber C. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA. 1993:269:2246-2248.
8. Chambers CD, Johnson KA, Dick LN, Felix PJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996:335:1010-1015.
9. Nulman I, RovetJ, StewartDE, etal, fortheMotherisk Program, Hospital for Sick Children and University of Toronto. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med. 1997:336:258-262.
10. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. JAMA. 1998:279:609-610.
11. American Medical Association. Drug interactions and adverse drug reactions. In: AMA Drug Evaluations. Chicago. Ill: American Medical Association; 1983:31-44.
12. Jones KL, Smith DW, Streissguth AP, Myrianthopoulos NC. Outcome in offspring of chronic alcoholic women. Lancet. 1974;7866:1076-1078.
13. Wilson JG. Current status of teratology: general principles and mechanisms derived from animal studies. In: Wilson JG. Fraser FC, eds. Handbook of Teratology, General Principles and Etiology. Vol 1. New York, NY: Plenum Press; 1977:47-74.
14. Moore KL, Persaud TV. The Developing Human: Clinically Oriented Embryology. 6th ed. Philadelphia, Pa: WB Sauriders Co; 1998.
15. HutchingsDE. Behavioral teratology: a new frontier in neurobehavioral research. In: Johnson EM, KochharDM, eds. Teratogenesis and Reproductive Toxicology. New York, NY: Springer Verlag; 1983:207-235.
16. Altshuler L, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry. 1996;153:592-606.
17. Robert E. Treating depression in pregnancy. N Engl JMed. 1996;335:1056-1058.
18. Cohen LS, Rosenbaum JF. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1997; 335:872-873.
19. Gracious BL, Wisner KL. Phenelzine use throughout pregnancy and the puerperium period: case report, review of the literature, and management recommendations. Depress Anxiety. 1997;6:124-128.
20. Pavy TJ, Kliff er AP, Douglas MJ. Anesthetic management of labour and delivery in a woman taking long-term MAOI. Can J Anesth. 1995:42:618-620.
21. Leppig KA, Werler MM, Cann CI, et al. Predictive value of minor anomalies, I: association with major malformations. J Pediatr. 1937;110:530-537.
22. Steer RA. Scholl TO, Hediger ML. Fischer RL. Selfreported depression and negative pregnancy outcomes. J Clin Epidemiol. 1992:45:1093-1099.
23. Zuckerman B, Bauchner H, Parker S, Cabrai H. Maternal depressive symptoms during pregnancy and newbom irritability.7Devßen,3YPecfc!jr.1990;11:190-194.
24. Eggermont E, Raveschat J, Deneve V, et al. The adverse influence of imipramine on thé adaptation of the newborn infant to extrauterine life. Acte Paediatr Belg. 1972:26:197-204.
25. Cowe L, Lloyd DJ, Dawling S. Neonatal convulsions caused by withdrawal from maternal clomipramine. BMJ. 1982:284:1837-1838.
26. Webster, PA. Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet. 1973;2:318-319.
27. Wisner KL, Perel JM. Psychopharmacologic agents and electroconvulsive therapy during pregnancy and the puerperium. In: Cohen RL, ed. Psychiatric Consultation in Childbirth Settings. New York. NY: Plenum; 1988:165-206.
28. KentLS, LaidlawJD. Suspected congenital sertraline dependence. ßr./Psvc/7/af/y. 1995:167:412-413.
29. Livezey GT, Rayburn WF. Principles of perinatal pharmacology. In: Rayburn WF, Zuspan FP, eds. Drug Therapy in Obstetrics and Cynecology. 3 rd ed. St Louis, Mo: Mosby-Year Book Inc; 1992:3-12.
30. Wisner KL, Perel JM, Wheeler SB. Tricydic dose requirements across pregnancy. Am 1 Psychiatry. 1993; 150:1541-1542.
31. Wadelius M, Darj E, Prenne G, Rane A. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther. 1997162:400-407.
32. Ferez V, Gorodisch S, Casavilla F, Maruffo C. Ultrastructure of human liverat the end of normal pregnancy. Am l Obstet.Cynecol. 1971;110:428-431.
33. Wisner KL, Perel JM, Peindl KS, Findling RL, Hanusa BH. Effects of the postpartum period on nortriptyline pharmacokinetics. Psychopharmacol Bull. 1997; 33:243-248.
34. Sandman CA, Wadhwa PD, Dunkel-Schetter C, et al. Psychobiological influences of stress and HPA regulation on the human fetus and infant birth outcomes. Ann N YAcadSci. 1994;739:198-210.
35. Wadhwa PD, Sandman CA, Porto M, DunkelSchetter C, Garite TJ. The association between prenatal stress and infant birth weight and gestational age at birth: a prospective investigation. Am J Obstet Cynecol. 1993;169:858-865.
36. Wisner KL, Stowe ZN. Psychobiology of postpartum mood disorders. Semin ReprodEndocrinol. 1997; 15:77-90.
37. Istvan J. Stress anxiety, and birth outcomes: a critical review of the evidence. Psychol Bull. 1986;100: 331-348.
38. Bogardus S, Holmboe E, Jekel JF. Perils, pitfalls, and possibilities in talking about medical risk. JAMA. 1999;281:1037-1041.
39. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 4th ed. Baltimore, Md: Williams 1994.
40. Center for Drug Evaluation and Research notice of part 15 hearings. Prescription drugs and biological products labeling. 97 Federal Register 20247 (1997).
41. Peindl KS, Day NL, Wisner KL. Alcohol use during pregnancy. Prim Psychiatry. 1996:3:43-46.
42. Berkowitz GS, Papiernik E. Epidemiology of preterm birth. Epidemiol Rev. 1993:15:414-443.
43. Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome P4503A. J Clin Psychopharmacol. 1995;15:387-398.
44. Lane RM. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol. 1996;11:31-61.
45. Zimmerman M, Coryell W, Corenthal C, et al. A self-report scale to diagnose major depressive disorder. Arch Gen Psychiatry. 1986;43:1076-1081.
46. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960:23:56-62.
47. Guy W. £arly Clinical Drug Evaluation Unit AssessmentManualforPsychopharmacology. Rockville, Md: National Institute of Mental Health; 1976:76-338.
48. American Psychiatric Association. Diagnostic and Statistical Manual for DSM-IV. In: Diagnostic and Statistic jl Manual of Mental Disorders, Fourth Edition. Washington, DC; American Psychiatric Association; 1994:1255.